Literature DB >> 2614725

Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate.

R A Maselli1, D J Nelson, D P Richman.   

Abstract

1. The effects of anti-acetylcholine receptor (AChR) monoclonal antibodies (mAbs) 370 and 132A on miniature end-plate potentials (MEPPs) and end-plate currents (EPCs) in the posterior latissimus dorsi muscle of adult chickens were investigated. 2. After incubation of the electrophysiological preparation with mAb 370 (5-50 micrograms/ml), which blocks both agonist (carbamylcholine) and alpha-bungarotoxin (alpha-BTX) binding and induces a hyperacute form of experimental autoimmune myasthenia gravis (EAMG), MEPP and EPC amplitudes were irreversibly reduced. 3. This effect was not associated with any significant change in the time constant describing EPC decay (tau EPC), current reversal potential, or the voltage dependence of tau EPC. The tau EPC at -80 mV was 5.9 +/- 0.6 ms before incubation with mAb 370 (50 micrograms/ml) and 6.0 +/- 0.9 ms afterwards. Current reversal potential was -3.9 +/- 0.4 mV before mAb incubation and -4.8 +/- 1.5 mV afterwards. The change in membrane potential required to produce an e-fold change in tau EPC was 128 +/- 2.3 mV before antibody incubation compared to 125 +/- 6.6 mV after incubation. 4. A second anti-AChR mAb, 132A (50 micrograms/ml), which is capable of inducing the classically described form of EAMG without blocking agonist or alpha-BTX binding, or inducing hyperacute EAMG, produced no significant change in MEPP amplitude, EPC amplitude, tau EPC or EPC reversal potentials. 5. The mAb 370 (50 micrograms/ml) induced a partially reversible decrease of the quantal content of the neurally evoked end-plate potential (EPP). This effect was not observed with mAb 132A, (+)tubocurarine (10(-7)-10(-5) g/ml) or an irrelevant anti-oestrogen receptor mAb. 6. These data suggest that the rapid onset of weakness observed in chicken hatchlings after the injection of mAb 370 (Gomez & Richman, 1983) can be attributed to a combined effect of a block of acetylcholine (ACh)-induced ion channel activity in the postsynaptic membrane and a reduction of the neurally evoked release of acetylcholine from the nerve terminal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2614725      PMCID: PMC1190524          DOI: 10.1113/jphysiol.1989.sp017573

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  43 in total

1.  The effect of magnesium on the activity of motor nerve endings.

Authors:  J DEL CASTILLO; B KATZ
Journal:  J Physiol       Date:  1954-06-28       Impact factor: 5.182

2.  Action of antibodies directed against the acetylcholine receptor on channel function at mouse and rat motor end-plates.

Authors:  J O Dolly; M Gwilt; G Lacey; J Newsom-Davis; A Vincent; P Whiting; D W Wray
Journal:  J Physiol       Date:  1988-05       Impact factor: 5.182

3.  Monoclonal antibodies as probes of the alpha-bungarotoxin and cholinergic binding regions of the acetylcholine receptor.

Authors:  M Mihovilovic; D P Richman
Journal:  J Biol Chem       Date:  1987-04-15       Impact factor: 5.157

4.  Monoclonal antibodies modify acetylcholine-induced ionic channel properties in cultured chick myoballs.

Authors:  G Goldberg; D Mochly-Rosen; S Fuchs; Y Lass
Journal:  J Membr Biol       Date:  1983       Impact factor: 1.843

5.  Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiologic criteria.

Authors:  C M Gomez; D P Richman
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

6.  Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture.

Authors:  S Bevan; R W Kullberg; S F Heinemann
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

7.  Affinity labeling of neuronal acetylcholine receptor subunits with an alpha-neurotoxin that blocks receptor function.

Authors:  S W Halvorsen; D K Berg
Journal:  J Neurosci       Date:  1987-08       Impact factor: 6.167

8.  An analysis of the action of a false transmitter at the neuromuscular junction.

Authors:  D Colquhoun; W A Large; H P Rang
Journal:  J Physiol       Date:  1977-04       Impact factor: 5.182

9.  Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site.

Authors:  D Mochly-Rosen; S Fuchs
Journal:  Biochemistry       Date:  1981-09-29       Impact factor: 3.162

10.  Neuromuscular Transmission in experimental autoimmune myasthenia gravis (EAMG). Quantitative ionophoresis and current fluctuation analysis at normal and myasthenic rat end-plates.

Authors:  R Hohlfeld; R Sterz; I Kalies; K Peper; H Wekerle
Journal:  Pflugers Arch       Date:  1981-05       Impact factor: 3.657

View more
  4 in total

1.  Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms.

Authors:  Christopher M Gomez; Ricardo A Maselli; Bhupinder P S Vohra; Manuel Navedo; Joel R Stiles; Pierre Charnet; Kelly Schott; Legier Rojas; John Keesey; Anthony Verity; Robert W Wollmann; Jose Lasalde-Dominicci
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

2.  Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction.

Authors:  C M Gomez; R Maselli; J E Gundeck; M Chao; J W Day; S Tamamizu; J A Lasalde; M McNamee; R L Wollmann
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

3.  Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions.

Authors:  Rumi Sato; Shiho Imamoto; Iku Utsnomiya; Terumasa Chiba; Kyoji Taguchi; Kenji Abe; Keiko Tanaka; Tadashi Miyatake
Journal:  Neurol Sci       Date:  2013-02-07       Impact factor: 3.307

4.  Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor.

Authors:  J Bufler; S Kahlert; S Tzartos; K V Toyka; A Maelicke; C Franke
Journal:  J Physiol       Date:  1996-04-01       Impact factor: 5.182

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.